Clinical Trial Update: Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rivipansel (GMI-1070) for treating vaso-occlusive crisis in hospitalized patients with sickle cell disease has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Rivipansel (rivipansel)

Snippet

Sponsor: Biossil Inc. | Conditions: Anemia, Sickle Cell | Phase 3 | Status: COMPLETED | Results posted: 2025-03-11